{
    "clinical_study": {
        "@rank": "109269", 
        "arm_group": [
            {
                "arm_group_label": "BDP/FF/GB", 
                "arm_group_type": "Experimental", 
                "description": "CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "arm_group_type": "Active Comparator", 
                "description": "Tiotropium bromide 18 mcg"
            }, 
            {
                "arm_group_label": "BDP/FF + Tiotropium", 
                "arm_group_type": "Active Comparator", 
                "description": "BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily\nBDP/FF/GB versus BDP/FF + Tiotropium"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the triple combination of beclometasone\n      dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of\n      severe COPD patients (chronic obstructive pulmonary disease)"
        }, 
        "brief_title": "Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "A 52-WEEK, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, 3-ARM PARALLEL GROUP, ACTIVE CONTROLLED\n      CLINICAL TRIAL OF FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE\n      PLUS GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5993) VERSUS TIOTROPIUM BROMIDE AND\n      VERSUS FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE ADMINISTERED\n      VIA PMDI AND TIOTROPIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE\n\n      A total of 8 clinic visits (V0 to V7) will be performed during the study, as follows:\n\n        -  A pre-screening visit (V0) to obtain the written informed consent from the patient\n\n        -  A screening visit (V1) to establish the eligibility of patients, followed by a 2-week\n           open-label run-in under Tiotropium\n\n        -  After the randomisation (V2), patients will be assessed after 4, 12, 26, 40 and 52\n           weeks of treatment (V3 to V7) The assessments performed at visits include routine\n           haematology and blood chemistry, medical history, physical examination, a 12-lead ECG,\n           spirometric parameters, vital signs).\n\n      During the run-in and the randomised treatment periods, patients use an e-diary to record\n      symptoms, rescue medication use and compliance to the study medications daily.\n\n      AEs/SAEs and COPD exacerbations will be monitored."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female COPD patients aged \u2265 40 years\n\n          -  Current smokers or ex-smokers\n\n          -  FEV1<50% predicted (FEV1/FVC <0,7)\n\n          -  at least 1 documented exacerbations in the last 12 Mo\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women and all women physiologically capable of becoming\n             pregnant\n\n          -  Diagnosis of asthma, history of allergic rhinitis or atopy\n\n          -  Patients treated for exacerbations 1 Mo prior to screening\n\n          -  Patients treated with non-cardioselective \u03b2-blockers\n\n          -  Patients treated with long-acting antihistamines\n\n          -  Known respiratory disorders other than COPD\n\n          -  Patients who have clinically significant cardiovascular condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "3686", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911364", 
            "org_study_id": "CCD-1208-PR-0090"
        }, 
        "intervention": [
            {
                "arm_group_label": "BDP/FF/GB", 
                "intervention_name": "BDP/FF/GB", 
                "intervention_type": "Drug", 
                "other_name": "CHF 5993 pMDI 100/6/12.5 mcg"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "intervention_name": "Tiotropium", 
                "intervention_type": "Drug", 
                "other_name": "Spiriva 18 mcg 1 capsule o.d"
            }, 
            {
                "arm_group_label": "BDP/FF + Tiotropium", 
                "intervention_name": "BDP/FF + Tiotropium", 
                "intervention_type": "Drug", 
                "other_name": "Foster 100/6 mcg 2 inhalations bid + Spiriva 18 mcg o.d."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol", 
                "Tiotropium", 
                "Glycopyrrolate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Frequent exacerbators", 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hesse", 
                        "country": "Germany"
                    }, 
                    "name": "Institut f\u00fcr klinische Forschung"
                }, 
                "investigator": {
                    "last_name": "Sabine Ballenberger", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary"
                    }, 
                    "name": "Csongr\u00e1d Megyei Mellkasi Betegs\u00e9gek Szakk\u00f3rh\u00e1za"
                }, 
                "investigator": {
                    "last_name": "Beatrix Balint", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perugia", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Perugia"
                }, 
                "investigator": {
                    "last_name": "Maurizio Dottorini", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Hungary", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "s.petruzzelli@chiesi.com", 
            "last_name": "Stefano Petruzzelli, MD, Prof", 
            "phone": "+390521279744"
        }, 
        "overall_contact_backup": {
            "email": "g.cohuet@chiesi.com", 
            "last_name": "Geraldine Cohuet", 
            "phone": "+33147684146"
        }, 
        "overall_official": {
            "affiliation": "Respiratory Research Group, Wythenshawe Hospital, MANCHESTER", 
            "last_name": "Jorgen Vestbo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Moderate and severe COPD exacerbation rate over 52 weeks of treatment.", 
            "measure": "COPD exacerbation rate", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911364"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change from baseline in pre-dose morning FEV1 at Week 52.", 
            "measure": "pre-dose morning FEV1", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}